Citations

Showing 10 of 108094 citations.

Patient and Caregiver-Derived Health Service Improvements for Better Critical Care Recovery
Leggett, Nina , Hibbert, Elizabeth , Hall, Tarli, Boehm, Leanne M. , Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Eaton, Tammy L. , Harris, Wendy, Hope, Aluko A. , Jackson, James C. , Johnson, Annie, Kloos, Janet A. , Korzick, Karen , MacTavish, Pamela , Meyer, Joel , Montgomery-Yates, Ashley , Slack, Andrew, Wade, Dorothy , Still, Mary, Netzer, Giora, Hopkins, Ramona O., Iwashyna, Theodore J. , McPeake, Joanne , Sevin, Carla M. , Initiative, on behalf of the Society of Critical Care Medicine’s Thrive, Haines, Kimberley , Quasim, Tara , Mikkelsen, Mark E. , Initiative, on behalf of the Society of Critical Care Medicine’s Thrive

Mayo Clinic

Critical Care Medicine | October 7, 2022 | Volume: 50 | Issue: 12 | Pages: 1778-1787

10.1097/ccm.0000000000005681 | PMID 36205494 Get It

OBJECTIVES: To engage critical care end-users (survivors and caregivers) to describe their emotions and experiences across their recovery trajectory, and elicit their ideas and solutions for health service improvements to improve the ICU recovery experience. DESIGN: End-user engagement as part of a qualitative design using the Framework Analysis method. SETTING: The Society of Critical Care Medicine’s THRIVE international collaborative sites (follow-up clinics and peer support groups). SUBJECTS: Patients and caregivers following critical illness and identified through the collaboratives. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Eighty-six interviews were conducted. The following themes were identified: 1) Emotions and experiences of patients—“Loss of former self; Experiences of disability and adaptation”; 2) Emotions and experiences of caregivers—“Emotional impacts, adopting new roles, and caregiver burden; Influence of gender roles; Adaptation, adjustment, recalibration”; and 3) Patient and caregiver-generated solutions to improve recovery across the arc of care—“Family-targeted education; Expectation management; Rehabilitation for patients and caregivers; Peer support groups; Reconnecting with ICU post-discharge; Access to community-based supports post-discharge; Psychological support; Education of issues of ICU survivorship for health professionals; Support across recovery trajectory.” Themes were mapped to a previously published recovery framework (Timing It Right) that captures patient and caregiver experiences and their support needs across the phases of care from the event/diagnosis to adaptation post-discharge home. CONCLUSIONS: Patients and caregivers reported a range of emotions and experiences across the recovery trajectory from ICU to home. Through end-user engagement strategies many potential solutions were identified that could be implemented by health services and tested to support the delivery of higher-quality care for ICU survivors and their caregivers that extend from tertiary to primary care settings.
Using Wet Bulb Globe Temperature and Physiological Equivalent Temperature as Predicative Models of Medical Stress in a Marathon: Analysis of 30 Years of Data From the Twin Cities Marathon
Schroeder, Allison N. , Suriano, Zachary J. , Asplund, Chad A., Roberts, William O. , Kliethermes‌, Stephanie

Mayo Clinic

Clinical Journal of Sport Medicine | October 7, 2022 | Volume: 33 | Issue: 1 | Pages: 45-51

10.1097/jsm.0000000000001079 | PMID 36205927 Get It

Objectives : Assess the relationships between wet bulb globe temperature (WBGT) and physiologic equivalent temperature (PET) at the start of a northern latitude marathon and their associations with medical stress and transfers to the emergency room (ER) when the race environment is unexpectedly warm, and participants are not acclimatized. Design : Retrospective review. Setting : Twin Cities Marathon from 1990 to 2019. Participants : Runners competing in the Twin Cities Marathon. Independent variables : Start WBGT (prospectively collected) and PET (retrospectively calculated). Main Outcome Measures : Marathon race starters and finishers and race day medical data (eg, medical stress, number of medical encounters, and number of ER visits). Results : The mean WBGT was 7.4°C (range −1.7°C to 22.2°C), and the meant PET was 5.2°C (range −16.7°C to 25.9°C). PET was not determined to be a significant predictor of medical stress (P = 0.71); however, a significant quadratic association between WBGT and medical stress was found (P = 0.006). WBGT (P = 0.002), but not PET (P = 0.07), was a significant predictor of the number of ER visits. Conclusions: Start WBGT was a better predictor of medical stress and ER visits than PET at the Twin Cities Marathon over a 30-year period. The start WBGT may be a better tool to predict race day environment medical safety.
Faculty Opinions recommendation of Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742343584.793595773 Get It

Editorial Comment
Stern, Karen , Stern, Karen L, Stern, Karen L

Mayo Clinic

Journal of Urology | October 7, 2022 | Volume: 208 | Issue: 5 | Pages: 1082-1082

10.1097/ju.0000000000002864.01 | PMID 36205345 Get It

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
Ray, Kausik K. , Raal, Frederick J. , Kallend, David , Jaros, Mark, Köenig, Wolfgang , Landmesser, Ulf , Schwartz, Gregory G. , Lawrence, David , Friedman, Andrew , Conde, Lorena Garcia , Wright, R. Scott , investigators, ORION Phase III, Landmesser, Ulf , Schwartz, Gregory G , Wright, R Scott , Raal, Frederick J , Koenig, Wolfgang , Ray, Kausik K , Leiter, Lawrence A. , investigators, ORION Phase III

Mayo Clinic

European Heart Journal | October 7, 2022 | Volume: 44 | Issue: 2 | Pages: 129-138

10.1093/eurheartj/ehac594 | PMID 36331326 Get It

Abstract Background Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a lower risk of cardiovascular (CV) events is not yet established. Methods and results Patient-level, pooled analysis of ORION-9, −10 and −11, included patients with heterozygous familial hypercholesterolaemia, atherosclerotic CV disease (ASCVD), or ASCVD risk equivalent on maximally tolerated statin-therapy, randomized 1:1 to receive 284 mg inclisiran or placebo on Days 1, 90, and 6-monthly thereafter for 18 months. Prespecified exploratory endpoint of major cardiovascular events (MACEs) included non-adjudicated CV death, cardiac arrest, non-fatal myocardial infarction (MI), and fatal and non-fatal stroke, evaluated as part of safety assessments using a standard Medical Dictionary for Regulatory Activities basket. Although not prespecified, total fatal and non-fatal MI, and stroke were also evaluated. Mean LDL-C at baseline was 2.88 mmol/L. At Day 90, the placebo-corrected percentage reduction in LDL-C with inclisiran was 50.6%, corresponding to an absolute reduction of 1.37 mmol/L (both P < 0.0001). Among 3655 patients over 18 months, 303 (8.3%) experienced MACE, including 74 (2.0%) fatal and non-fatal MIs, and 28 (0.8%) fatal and non-fatal strokes. Inclisiran significantly reduced composite MACE [OR (95% CI): 0.74 (0.58–0.94)], but not fatal and non-fatal MIs [OR (95% CI): 0.80 (0.50–1.27)] or fatal and non-fatal stroke [OR (95% CI): 0.86 (0.41–1.81)]. Conclusion This analysis offers early insights into the potential CV benefits of lowering LDL-C with inclisiran and suggests potential benefits for MACE reduction. These findings await confirmation in the larger CV outcomes trials of longer duration.
In Vivo Prediction of Kidney Stone Fragility Using Radiomics-Based Regression Models
Pillai, Parvathy Sudhir , Hsieh, Scott S. , Vercnocke, Andrew J. , Potretzke, Aaron M. , Koo, Kevin , Ferrero, Andrea , Sudhir Pillai, Parvathy, McCollough, Cynthia H.

Mayo Clinic

Journal of Endourology | October 7, 2022 | Volume: 37 | Issue: 4 | Pages: 443-452

10.1089/end.2022.0483 | PMID 36205579 Get It

Introduction: The surgical technique for urinary stone removal is partly influenced by its fragility, as prognosticated by the clinician. This feasibility study aims to develop a linear regression model from CT-based radiomic markers to predict kidney stone comminution time in vivo with two ultrasonic lithotrites. Materials and Methods: Patients identified by urologists at our institution as eligible candidates for percutaneous nephrolithotomy were prospectively enrolled. The active engagement time of the lithotrite in breaking the stone during surgery denoted the comminution time of each stone. The comminution rate was computed as the stone volume disintegrated per minute. Stones were grouped into three fragility classes (fragile, moderate, hard), based on inverse of the comminution rates with respect to the mean. Multivariable linear regression models were trained with radiomic features extracted from clinical CT images to predict comminution times in vivo . The model with the least root mean squared error (RMSE) on comminution times and the fewest misclassification of fragility was finally selected. Results: Twenty-eight patients with 31 stones in total were included in this study. Stones in the cohort averaged 1557 (±2472) mm 3 in volume and 5.3 (±7.4) minutes in comminution time. Ten stones had nonmoderate fragility. Linear regression of stone volume alone predicted comminution time with an RMSE of 6.8 minutes and missed all 10 stones with nonmoderate fragility. A fragility model that included stone volume, internal morphology, shape-based radiomics, and device type improved RMSE to below 3.3 minutes and correctly classified 20/21 moderate and 6/10 nonmoderate stones. Conclusions: CT metrics-based fragility models may provide information to surgeons regarding kidney stone fragility and facilitate the selection of stone removal procedures.
Three-Year Interval for the Multi-Target Stool DNA Test for Colorectal Cancer Screening: A Longitudinal Study
Imperiale, Thomas F. , Lavin, Philip T. , Marti, Tara N. , Jakubowski, Debbie , Itzkowitz, Steven H. , May, Folasade P. , Limburg, Paul J. , Sweetser, Seth , Daghestani, Anas , Berger, Barry M. , Limburg, Paul J

Mayo Clinic

Cancer Prevention Research | October 7, 2022 | Volume: 16 | Issue: 2 | Pages: 89-97

10.1158/1940-6207.capr-22-0238 | PMID 36205504 Get It

Abstract Data supporting the clinical utility of multi-target stool DNA (mt-sDNA) at the guideline-recommended 3-year interval have not been reported. Between April 2015 and July 2016, candidates for colorectal cancer screening whose providers prescribed the mt-sDNA test were enrolled. Participants with a positive baseline test were recommended for colonoscopy and completed the study. Those with a negative baseline test were followed annually for 3 years. In year 3, the mt-sDNA test was repeated and colonoscopy was recommended independent of results. Data were analyzed using the Predictive Summary Index (PSI), a measure of the gain in certainty for dichotomous diagnostic tests (where a positive value indicates a net gain), and by comparing observed versus expected colorectal cancers and advanced precancerous lesions. Of 2,404 enrolled subjects, 2,044 (85%) had a valid baseline mt-sDNA result [284 (13.9%) positive and 1,760 (86.1%) negative]. Following participant attrition, the year 3 intention to screen cohort included 591 of 1,760 (33.6%) subjects with valid mt-sDNA and colonoscopy results, with no colorectal cancers and 63 advanced precancerous lesions [22 (34.9%) detected by mt-sDNA] and respective PSI values of 0% (P = 1) and 9.3% (P = 0.01). The observed 3-year colorectal cancer yield was lower than expected (one-sided P = 0.09), while that for advanced precancerous lesions was higher than expected (two-sided P = 0.009). Repeat mt-sDNA screening at a 3-year interval resulted in a statistically significant gain in detection of advanced precancerous lesions. Due to absence of year 3 colorectal cancers, the PSI estimate for colorectal cancer was underpowered and could not be reliably quantified. Larger studies are required to assess the colorectal cancer study findings. Prevention Relevance: Understanding the 3-year yield of mt-sDNA for colorectal cancer and advanced precancerous polyps is required to ensure the clinical appropriateness of the 3-year interval and to optimize mt-sDNA's screening effectiveness.
Tinea Capitis Visualized With Wood’s Lamp
Alzahrani, Fatmah , Lovett, Audrey

Mayo Clinic

Journal of Cutaneous Medicine and Surgery | October 7, 2022 | Volume: 27 | Issue: 3 | Pages: 300-300

10.1177/12034754221130030 | PMID 36205176 Get It